The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

This is to inform you that the following Lot No. 24299 of Aminocaproic Acid Injection, USP manufactured and distributed by American Regent, Inc. is the subject of a Recall. Recall of this product to RETAIL LEVEL was initiated due to particulate found during Reject Characterization.

Aminocaproic Acid Injection is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, fresh whole blood transfusions, fibrinogen infusions, and other emergency measures may be required.

The administration of an injectable product containing particulate matter could potentially result in phlebitis, capillary occlusion, thromboembolism, or an immunologic or immunogenic response. When Aminocaproic Acid Injection, USP is used according to the approved prescribing procedures, at this time there is low potential risk of the particle entering the systemic circulation with consequent adverse reactions. As of July 24, 2026, American Regent, Inc. has not received any reports of adverse events related to this recall.

PRODUCT: Aminocaproic Acid Injection, USP 250 mg/mL 20 mL/vial

NDC NUMBER: 0517-9120-25

LOT NUMBER: 24299

EXPIRATION DATE: August 31, 2026